Optimizing combination therapy in the management of hypertension: The role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination

4Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

High blood pressure is the leading risk factor for death and disability worldwide, and the prevalence is increasing. Effective treatment decreases the risk of adverse events in proportion to blood pressure reduction. Combination antihypertensive therapy reduces blood pressure promptly and effectively. Single-pill combinations reduce the pill burden and improve adherence, efficacy, and tolerability of treatment compared with single drug pills. A significant portion of the hypertensive population will require three drugs for adequate control. The single-pill combination of aliskiren, amlodipine, and hydrochlorothiazide is based on complementary mechanisms of action. Clinical trials have shown it to be a safe and effective treatment for hypertension. This combination is a reasonable choice in clinical practice for patients with hypertension that requires three drugs for effective treatment. © 2013 Hovater and Jaimes, publisher and licensee Dove Medical Press Ltd.

Cite

CITATION STYLE

APA

Hovater, M. B., & Jaimes, E. A. (2013, June 17). Optimizing combination therapy in the management of hypertension: The role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination. Integrated Blood Pressure Control. https://doi.org/10.2147/IBPC.S32649

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free